Recent extremely meaningful positive changes in investment behavior have benefitted Alnylam Pharmaceuticals Inc (NASDAQ: ALNY): its longer term price trend turned up, the stock’s recent price rise disrupted its longer term downtrend, positive upside/downside volume developed, and the stock rose on very heavy volume.
The stock is currently unrated.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, ALNY is expected to be a major Value Eraser.
Alnylam Pharmaceuticals is currently unrated.
Recent Price Action
On 6/25/24, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) stock enjoyed a very large increase of 7.7%, closing at $240.15. Moreover, trading volume in this advance was exceptionally high at 524% of normal. The stock has risen 49.7% during the last week but has been weak relative to the market over the last nine months.
Be the first to comment